NewPhase Clinical Trials Investigates Early Heart Attack Detection Device.

Online, February 14, 2012 (Newswire.com) - Miami, Florida: Today Dr. Juan Carlo Londoño, site Principal Investigator of NewPhase Clinical Trials announced its first implant of the AngelMed Guardian cardiac monitor and alert system. The system is designed to reduce the time it takes patients to get to the emergency room during an impending heart attack. Dr. Londoño, led the NewPhase Clinical Trials team to perform one of the first implants in the state of Florida and is among the very first physicians across the United States to implant the experimental device.

The AngelMed Guardian system is designed to track significant changes in the heart's electrical signal and then alert patients to seek medical attention in anticipation of a heart attack. The objective of the ALERTS Pivotal Study is to provide an assessment of the safety and effectiveness of the AngelMed Guardian System.

Humberto Alvarez, a Miami Florida resident, is one of the first patients in Miami enrolled in the ALERTS study to receive the AngelMed Guardian System. Mr. Alvarez is a 65 year old Hispanic male with diabetes who had his first heart attack one year ago, but didn't recognize his symptoms until two days after the event. He received a balloon angioplasty and a coronary stent to unblock his arteries. Last July, he had another episode of chest discomfort and angina requiring hospitalization. Mr. Alvarez was successfully implanted with the device on January 20th, 2012 by Dr. Londoño's team.

"We know that patients receiving early treatment after the onset of symptoms of a heart attack do better and live longer than those who present late. If we can get heart attack patients into the
hospital even earlier or before symptoms start, their prognosis and outcome should subsequently improve" states Dr. Londoño.

According to the American Heart Association, one of every five deaths in the U.S. is attributable to coronary heart disease. Further, 50% of heart-attack fatalities occur within one hour of symptom onset and occur before the patient even reaches the hospital.

The AngelMed Guardian System is comprised of an internal implantable device about the size of a standard pacemaker with a lead into the heart, an external telemetry device, and a programmer that aids physicians in evaluating heart signals.

NewPhase Clinical Trials is among the first medical facilities to participate in the AngelMed Guardian system trial. To participate in the ALERTS study, patients must meet various inclusion criteria. For more information on the AngelMed Guardian
system or the ALERTS study protocol, contact Lourdes Gonzalez, Research Coordinator, NewPhase Clinical Trials at 305-858-4300 or lourdes@nextphaseresearch.com

Forward Looking Statements: Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.